MAHA
As of July 15, 2026

MAHA Initiative Dashboard

Make America Healthy Again — Federal Priorities, State Adoption & Projected Outcomes
State Adoption of MAHA-Aligned Initiatives
Toggle categories to recompute the adoption intensity score. Hover a state for a summary; click for full detail.
Projected Impact
Adjust the projection year and scope to recompute health, savings, attendance, initiative, and binding-action estimates.
Projection scope
Year 1 Projections
Year 1Year 5Year 10Year 15Year 20
Current model National aggregate 49 active jurisdictions · 100% U.S. population 34 adoption intensity
Modeled Outcome Trajectories (Years 1–20)
Shaded areas show low–high confidence bands; the green marker tracks the year selected on the slider.
Data Sources
  • Federal initiative status: agency websites, Federal Register notices, congressional records, Executive Orders 14212 & 14297.
  • State initiatives: state legislative databases and the USDA FNS SNAP waiver tracker ↗.
  • Baselines: CDC NHANES 2021–2023 (childhood obesity 19.7%), CDC National Diabetes Statistics Report 2024, Milken Institute 2023 (chronic-disease cost burden ~$3.7T).
  • HHS mark per uploaded source [1].
Projection Methodology

The adoption intensity score = (Σ status_weight × binding_multiplier) / 24 × 100, where implemented=3, passed=2, proposed=1, and binding=1.5×, voluntary=1.0×. California (raw 24) sets the maximum.

National projections scale literature effect sizes by the population-weighted average adoption score (34 → factor 0.34). Diminishing returns apply logarithmically after Year 10; economic savings compound 3–5% annually. State projections scale national values by (state score ÷ 34), with economic metrics additionally scaled by population share.

Benchmark studies: Waters et al. 2011 (Cochrane), Tuomilehto et al. 2001 (NEJM), Puska et al. 2009 (North Karelia), Adolphus et al. 2013, Frisvold 2015, Goetzel et al. 2014, Loeppke et al. 2009, McCann et al. 2007 (Lancet).

Limitations & Caveats

Roughly 60% of catalogued federal actions are non-binding (study directives, voluntary programs, proposed rules). Only ~40% carry the force of law. The synthetic-dye phase-out relies primarily on voluntary industry commitments; several actions face active litigation.

Key limitations: small-to-large extrapolation, linear scaling of a likely-nonlinear dose-response, attribution against secular trends, variable implementation fidelity, multi-year outcome lags, and no modeled feedback loops. A score of 0 means zero documented activity as of the data cutoff, not necessarily zero activity.